Pulse of the Hill

The Definitive Fly-In Directory

AboutAlertsAdd Your Fly-InSign in

Bill Detail

H.R. 1672

Congress: 119

Title

Maintaining Investments in New Innovation Act

Summary

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Sponsor

Rep. Donald Davis [D-NC-1]

Status

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Status as of Jun 29, 1:29 AM · synced 19h ago

Introduced

2025-02-27

Open on Congress.govCongress.gov searchBack to directory

Data source mode: cache

Bill Engagement

Lobbyists on the case

6 orgs · 35 lobbyists · 14 filings mention H.R. 1672 (Maintaining Investments in New Innovation Act) in LDA disclosures.
Top orgs filing